Is X4 Pharmaceuticals Stock a Good Investment?
X4 Pharmaceuticals Investment Advice | XFOR |
- Examine X4 Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research X4 Pharmaceuticals' leadership team and their track record. Good management can help X4 Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact X4 Pharmaceuticals' business and its evolving consumer preferences.
- Compare X4 Pharmaceuticals' performance and market position to its competitors. Analyze how X4 Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if X4 Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about X4 Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in X4 Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if X4 Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine X4 Pharmaceuticals Stock
Researching X4 Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 58.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.5. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. X4 Pharmaceuticals last dividend was issued on the 14th of March 2019. The entity had 1:30 split on the 28th of April 2025.
To determine if X4 Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding X4 Pharmaceuticals' research are outlined below:
| X4 Pharmaceuticals generated a negative expected return over the last 90 days | |
| X4 Pharmaceuticals has high historical volatility and very poor performance | |
| X4 Pharmaceuticals may become a speculative penny stock | |
| X4 Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (37.45 M) with profit before overhead, payroll, taxes, and interest of 25.85 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (130.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| Roughly 58.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 787 shares by Arthur Taveras of X4 Pharmaceuticals at 1.0072 subject to Rule 16b-3 |
X4 Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in X4 Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to X4 Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact X4 Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises X4 Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-03 | 2022-09-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2025-03-19 | 2024-12-31 | -0.1575 | -0.2 | -0.0425 | 26 | ||
2024-03-21 | 2023-12-31 | -0.15 | -0.1 | 0.05 | 33 | ||
2023-03-21 | 2022-12-31 | -0.24 | -0.29 | -0.05 | 20 | ||
2023-05-04 | 2023-03-31 | -0.22 | -0.16 | 0.06 | 27 | ||
2024-08-08 | 2024-06-30 | 0.01 | -0.07 | -0.08 | 800 | ||
2024-05-07 | 2024-03-31 | -0.16 | -0.26 | -0.1 | 62 | ||
2022-05-12 | 2022-03-31 | -0.61 | -0.72 | -0.11 | 18 |
Know X4 Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as X4 Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading X4 Pharmaceuticals backward and forwards among themselves. X4 Pharmaceuticals' institutional investor refers to the entity that pools money to purchase X4 Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stifel Nicolaus Investment Advisors | 2025-03-31 | 0.0 | Lexaurum Advisors, Llc | 2025-06-30 | 0.0 | Nisa Investment Advisors, L.l.c. | 2025-03-31 | 0.0 | Gsa Capital Partners Llp | 2025-03-31 | 0.0 | Lpl Financial Corp | 2025-03-31 | 0.0 | Vontobel Holding Ltd. | 2025-03-31 | 0.0 | Hartland & Co | 2025-03-31 | 0.0 | Wealthcare Capital Partners, Llc | 2025-06-30 | 0.0 | Rhumbline Advisers | 2025-03-31 | 188.4 K | Sg Americas Securities, Llc | 2025-03-31 | 91.5 K | T. Rowe Price Associates, Inc. | 2025-03-31 | 83 K |
X4 Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.41 M.Market Cap |
|
X4 Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (1.69) | (1.78) |
Determining X4 Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if X4 Pharmaceuticals is a good buy. For example, gross profit margin measures X4 Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of X4 Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate X4 Pharmaceuticals' management efficiency
X4 Pharmaceuticals has return on total asset (ROA) of (0.5861) % which means that it has lost $0.5861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2175 %, meaning that it created $1.2175 on every $100 dollars invested by stockholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/06/2025, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.34. At this time, X4 Pharmaceuticals' Net Tangible Assets are relatively stable compared to the past year. As of 08/06/2025, Debt To Assets is likely to grow to 0.56, while Total Assets are likely to drop slightly above 108.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.11 | 0.10 | |
| Tangible Book Value Per Share | (0.03) | (0.02) | |
| Enterprise Value Over EBITDA | (161.29) | (169.35) | |
| Price Book Value Ratio | 199.80 | 209.79 | |
| Enterprise Value Multiple | (161.29) | (169.35) | |
| Price Fair Value | 199.80 | 209.79 | |
| Enterprise Value | 4.4 B | 4.3 B |
The management team at X4 Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 0.597 |
Basic technical analysis of XFOR Stock
As of the 6th of August, X4 Pharmaceuticals owns the market risk adjusted performance of (1.15), and Information Ratio of (0.16). In connection with fundamental indicators, the technical analysis model lets you check timely technical drivers of X4 Pharmaceuticals, as well as the relationship between them. Please check out X4 Pharmaceuticals market risk adjusted performance and treynor ratio to decide if X4 Pharmaceuticals is priced more or less accurately, providing market reflects its prevailing price of 1.61 per share. Please also validate X4 Pharmaceuticals jensen alpha, which is currently at (1.14) to confirm the company can sustain itself sooner or later.X4 Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific X4 Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on X4 Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases X4 Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
X4 Pharmaceuticals' Outstanding Corporate Bonds
X4 Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. X4 Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XFOR bonds can be classified according to their maturity, which is the date when X4 Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| XEROX HLDGS P Corp BondUS98421MAB28 | View | |
| XEROX HLDGS P Corp BondUS98421MAA45 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| US98420EAB11 Corp BondUS98420EAB11 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand X4 Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing X4 Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (687.71) | |||
| Standard Deviation | 7.1 | |||
| Variance | 50.43 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.14) | |||
| Total Risk Alpha | (2.05) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 31.39 | |||
| Value At Risk | (9.83) | |||
| Potential Upside | 16.22 | |||
| Skewness | 1.11 | |||
| Kurtosis | 1.62 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (1.15) | |||
| Mean Deviation | 5.19 | |||
| Coefficient Of Variation | (687.71) | |||
| Standard Deviation | 7.1 | |||
| Variance | 50.43 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.14) | |||
| Total Risk Alpha | (2.05) | |||
| Treynor Ratio | (1.16) | |||
| Maximum Drawdown | 31.39 | |||
| Value At Risk | (9.83) | |||
| Potential Upside | 16.22 | |||
| Skewness | 1.11 | |||
| Kurtosis | 1.62 |
Consider X4 Pharmaceuticals' intraday indicators
X4 Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of X4 Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
X4 Pharmaceuticals time-series forecasting models is one of many X4 Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary X4 Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
XFOR Stock media impact
There is far too much social signal, news, headlines, and media speculation about X4 Pharmaceuticals that are available to investors today. This information is accessible both publicly - through X4 Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of XFOR-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of X4 Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of X4 Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to X4 Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive X4 Pharmaceuticals alpha.
X4 Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards X4 Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
X4 Pharmaceuticals Corporate Management
| Brian Bowersox | VP Controller | Profile | |
| Renato Skerlj | Founder | Profile | |
| Arthur Taveras | Chief Officer | Profile | |
| Murray MD | Interim Director | Profile | |
| Mark MBA | Chief Officer | Profile |
Already Invested in X4 Pharmaceuticals?
The danger of trading X4 Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of X4 Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than X4 Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile X4 Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.